These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11301841)

  • 1. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
    Rocha Lima CM; Sherman CA; Brescia FJ; Brunson CY; Green MR
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):46-51. PubMed ID: 11301841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
    Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
    J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
    Rocha Lima CM; Leong SS; Sherman CA; Perkel JA; Putman T; Safa AR; Green MR
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):19-24. PubMed ID: 12109801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
    Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
    Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
    Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
    Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.
    Blackstock AW; Melin SA; Butler JM; Patton S; Pineau B; Albertson D; Howerton R; Levine E
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):25-8. PubMed ID: 12109802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
    Bhargava P; Jani CR; Savarese DM; O'Donnell JL; Stuart KE; Rocha Lima CM
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):23-6. PubMed ID: 14569844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
    Sun W; Haller D
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):16-9. PubMed ID: 14569842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel followed by gemcitabine and irinotecan in solid tumors.
    Rocha Lima CM; Urbanic JJ; Sherman CA; Brescia FJ; Green MR
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):37-45. PubMed ID: 11221020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
    Stathopoulos GP; Rigatos SK; Dimopoulos MA; Giannakakis T; Foutzilas G; Kouroussis C; Janninis D; Aravantinos G; Androulakis N; Agelaki S; Stathopoulos JG; Georgoulias V;
    Ann Oncol; 2003 Mar; 14(3):388-94. PubMed ID: 12598343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
    Mishra G; Butler J; Ho C; Melin S; Case LD; Ennever PR; Magrinat GC; Bearden JD; Minotto DC; Howerton R; Levine E; Blackstock AW
    Am J Clin Oncol; 2005 Aug; 28(4):345-50. PubMed ID: 16062075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
    Stathopoulos GP; Syrigos K; Aravantinos G; Polyzos A; Papakotoulas P; Fountzilas G; Potamianou A; Ziras N; Boukovinas J; Varthalitis J; Androulakis N; Kotsakis A; Samonis G; Georgoulias V
    Br J Cancer; 2006 Sep; 95(5):587-92. PubMed ID: 16909140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
    Chaudhary UB; Verma N; Keane T; Gudena V
    Am J Clin Oncol; 2014 Apr; 37(2):188-93. PubMed ID: 23241501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
    Rocha Lima CM; Eckardt JR; Leong SS; Sherman CA; Perkel JA; Putman T; Safa AR; Bahadori HR; Green MR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2. PubMed ID: 10585008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
    Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
    J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
    Rocha Lima CM; Savarese D; Bruckner H; Dudek A; Eckardt J; Hainsworth J; Yunus F; Lester E; Miller W; Saville W; Elfring GL; Locker PK; Compton LD; Miller LL; Green MR
    J Clin Oncol; 2002 Mar; 20(5):1182-91. PubMed ID: 11870159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
    Rocha Lima CM; Urbanic JJ; Lal A; Kneuper-Hall R; Brunson CY; Green MR
    Semin Oncol; 2001 Jun; 28(3 Suppl 10):34-43. PubMed ID: 11510032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.